Skip to main content

Press Releases

February 10, 2021
Collaboration leverages Caribou’s next-generation CRISPR genome editing technology platform and AbbVie’s antigen-specific binders
February 9, 2021

BERKELEY, Calif., February 9, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the appointment of Jason O’Byrne as Chief Financial Officer (CFO). An accomplished executive with more than 20 years of experience within high-growth biotechnology environments, Mr. O’Byrne most recently served as Senior Vice President of Finance at Audentes Therapeutics.

In the News

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23, 2021

“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”

AbbVie and Caribou Team Up On Next-Gen Off-the-Shelf CAR-T Therapies

February 18, 2021

“AbbVie and Caribou are partnering to develop next-generation off-the-shelf CAR-T therapies for oncology indications. The collaboration centres around Caribou’s chRDNA technology to overcome challenges facing existing off-the-shelf CAR-T therapies.”

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
+1 (617) 461-4023